학술논문
Quantitative Antibody Levels in Hospital Workers after Receiving three Doses of COVID-19 vaccines
Document Type
Report
Author
Sitompul, Pompini Agustina; Mariana, Nina; Budiman, Ervan; Tanjungsari, Dian Wahyu; Nugroho, Betha Ariesanty Anggraini; Hartono, Teguh Sarry; Jahiroh; Banggai, Christine Ernita; Widiantari, Aninda Dinar; Nugroho, Anita Puspitasari Dyah; Herlina; Suliati; Murtiani, Farida; Maemun, Siti; Syahril, Mohammad; Santoso, Wahyu Budi
Source
Biomedical and Pharmacology Journal. September 2022, Vol. 15 Issue 3, p1745, 5 p.
Subject
Language
English
ISSN
0974-6242
Abstract
The global pandemic was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). (1) We really need to control the spread of the outbreak and a global COVID-19 vaccination. (1) [...]
Hospital workers were at high risk for SARS-Cov-2 infection and the first population with authorized access to the three doses of vaccination against SARS-Cov-2 antigen. The study was aimed to compare SARS-Cov-2 antibody levels among hospital workers receiving the three doses of Covid-19 vaccines with a history of Covid-19 infection versus those without a history of infection. A cross sectional study was conducted at the Sulianti Saroso infectious Disease Hospital (SSIDH) in December 2021. The inclusion criteria were hospital workers in both subjects with and without previous Covid-19 infection and those who had received 3 doses of Covid-19 vaccines. Anti SARS-Cov-2 antibody levels measured by the Architect of SARS-Cov-2 IgG II Quant. There were 75 participants in the study, the median of anti SARS Cov-2 levels reported 8724.4 AU/mL (3396.8, 15773.2 AU/mL, interquartile range). They were divided into 2 groups according to the status of prior Covid-19 infection, hospital workers with and without previous of Covid-19 infection. There was no significance difference in antibody less than 25.000 AU/mL between hospital worker with and without previous Covid-19 infection (p = 1,000). Meanwhile, the median of antibody levels was seen in the interval between the 3rd dose of vaccine within 1 month; 2 to 3 months; 4 to 5 months before the antibody measurement (14576.5 AU/mL;12407.4 AU/mL; 5778.1 AU/mL, respectively). in this study, after three doses of Covid-19 vaccines, there was no significance difference in antibody levels of hospital worker with and without previous Covid-19 infection. Keywords: Abbott Architect; Antigen; SARS-CoV-2; Vaccination.
Hospital workers were at high risk for SARS-Cov-2 infection and the first population with authorized access to the three doses of vaccination against SARS-Cov-2 antigen. The study was aimed to compare SARS-Cov-2 antibody levels among hospital workers receiving the three doses of Covid-19 vaccines with a history of Covid-19 infection versus those without a history of infection. A cross sectional study was conducted at the Sulianti Saroso infectious Disease Hospital (SSIDH) in December 2021. The inclusion criteria were hospital workers in both subjects with and without previous Covid-19 infection and those who had received 3 doses of Covid-19 vaccines. Anti SARS-Cov-2 antibody levels measured by the Architect of SARS-Cov-2 IgG II Quant. There were 75 participants in the study, the median of anti SARS Cov-2 levels reported 8724.4 AU/mL (3396.8, 15773.2 AU/mL, interquartile range). They were divided into 2 groups according to the status of prior Covid-19 infection, hospital workers with and without previous of Covid-19 infection. There was no significance difference in antibody less than 25.000 AU/mL between hospital worker with and without previous Covid-19 infection (p = 1,000). Meanwhile, the median of antibody levels was seen in the interval between the 3rd dose of vaccine within 1 month; 2 to 3 months; 4 to 5 months before the antibody measurement (14576.5 AU/mL;12407.4 AU/mL; 5778.1 AU/mL, respectively). in this study, after three doses of Covid-19 vaccines, there was no significance difference in antibody levels of hospital worker with and without previous Covid-19 infection. Keywords: Abbott Architect; Antigen; SARS-CoV-2; Vaccination.